The Gastrointestinal Research Group
Associate Professor, Department of MedicineDirector, Inflammatory Bowel Disease Clinic
MD, University of Western Ontario; FRCPC
Dr. Panaccione is an internationally recognized expert in inflammatory bowel disease (IBD) which consists of Crohn's disease (CD) and ulcerative colitis (UC). His special interest lies in the implementation and performance of clinical trials of new therapies in IBD. He also performs research in identifying new targets to develop new therapies in IBD.
The University of Calgary IBD Clinical Trials Unit is ranked among the top five units in the world. In the last three years they have tested three new agents which have been approved for the treatment of IBD. The goal is to continue to develop therapies that will improve patient's quality of life and allow patients expanded choices.
Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosefeld MR, Kent JD, Pollack PF. Adalimumab Induction Therapy for Crohn's Disease Previously Treated with Infliximab. A randomized trial. Ann Intern Med 2007 Apr 30.
Sandborn WJ, Hanauer SB, Rutgeerts PJ, Fedorak RN, Lukas M, Macintosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for Maintenance of Crohn's Disease: Results of the CLASSIC II Trial. Gut. 2007 Feb 13.
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132(1): 52-65, 2007.
Panaccione R. The approach to dysplasia surveillance in inflammatory bowel disease. Can J Gastroenterol 20(4): 251-3, 2006.
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology 130(2): 323-33, 2006.
Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrence IC, Panaccione R, Sanders M, Schreiber S, Targan S. van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353(18): 1912-25, 2005.